Indivior Pharmaceuticals Inc. will raise $400 million through a private placement of convertible senior notes due 2031, offering qualified institutional buyers a 30‑day option to purchase an additional $60 million and the right to convert the debt into common stock under specified circumstances.
The company plans to use approximately $239 million of the net proceeds to repay borrowings under its term loan and revolving credit facility, and up to $75 million to repurchase shares from certain purchasers of the notes. The remaining proceeds will be allocated to general corporate purposes, providing flexibility to support ongoing operations and strategic initiatives.
The financing move allows Indivior to refinance existing debt while also creating a potential share‑repurchase program that could support the stock price. The convertible structure offers investors upside potential if the company’s equity performs well, while the debt component provides a fixed‑income return.
Investors expressed concern over the increased debt load and the potential dilution that could result if the notes are converted, which may influence the company’s valuation and capital‑structure outlook.
Indivior’s focus on opioid‑use‑disorder treatments has driven recent financial strength. In Q4 2025, the company reported revenue growth driven by Sublocade, a 20 % year‑over‑year increase in adjusted EBITDA, and an 83 % gross margin in FY 2023. Management guidance for 2026 projects mid‑teens dispense‑unit growth for Sublocade, operating expenses not exceeding $450 million, and approximately $300 million in cash flow from operations.
CEO Joe Ciaffoni noted in February 2026 that accelerated Subocade rollout and increased cash flow will enable strategic capital deployment, while CFO Ryan Preblick highlighted 13 % net revenue growth and 20 % adjusted EBITDA growth in 2025 and emphasized 2026 guidance for mid‑teens dispense‑unit growth and operating expenses under $450 million.
The convertible notes shift debt from bank‑style facilities to capital‑market funding, potentially at more favorable terms. The share‑repurchase program may support the share price but also signals the company’s view that its equity is undervalued and that it needs to offset dilution. Overall, the event could reshape Indivior’s balance sheet and capital structure in the coming years.
The offering represents a significant capital‑raising event that could impact Indivior’s financial profile and shareholder value.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.